Kurz gefasst
Fachartikel in der Zeitschrift Practical Diabetes, online erschienen am 06.02.2012. Verfasst von Priya George und 1 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Diazoxide was initially developed as a non-diuretic hypotensive agent, an action for which it is still used clinically, before it was also noted to have a significant hypoglycaemic effect. Diazoxide is primarily indicated for the treatment of severe hypertension (particularly when associated with renal disease) and chronic intractable hypoglycaemia occurring, for instance, in the context of an insulinoma. Research in the last few years has suggested other potential uses for diazoxide including hypo-glycaemia unawareness in type 1 diabetes (T1DM), hyperlipidaemia and obesity and, perhaps more surprisingly, type 2 diabetes (T2DM). See Figure 1. Diazoxide is a benzo-thiadiazine derivative (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1 dioxide), that is extensively protein bound (>90%) and is excreted by the kidneys. The plasma half-life following IV administration is 28±8.3 hours. The primary mode of action of diazoxide is through ATP-sensitive potassium (KATP) channels, which are a type of potassium channel gated by ATP and hence play a critical role as sensors of the metabolic status. KATP channels are composed of Kir6.x-type subunits and sulphonylurea receptor (SUR) subunits, along with some additional components. The Kir6.x- (either Kir6.1 or Kir6.2) subunits form the inward-rectifier potassium channel, while the SUR subunits (SUR1, SUR2A or SUR2B) are transmembrane proteins that allow nucleotide modulation of the potassium channel. The mechanism of action of diazoxide Diazoxide exerts its effects through binding to the SUR subunit of the KATP channel which has the effect of 'opening' the channel leading to increased potassium entry into the cell and hyperpolarisation of the cell membrane (inhibiting the generation of cell membrane potential). Sulphonylureas have the opposite action and, once bound to the SUR subunit of KATP channels, have the effect of 'closing' the channel. KATP channels are expressed within a number of cellular compartments (nucleus, sarcolemma, plasma membrane) and different tissues types, where the conformation of the channel largely determines its function. Pancreatic beta cells, for instance, express SUR1 and ATP-binding to SUR1 closes the KATP channel, depolarising the membrane and initiating a series of intracellular mechanisms that stimulate insulin release, an effect that is antagonised by diazoxide. In contrast, cardiac, skeletal and vascular and non-vascular smooth muscle predominantly contain KATP channels of the SUR2A subtype. Diazoxide binding to this subunit leads to vasodilation, hence its use as a treatment for severe hypertension and an explanation of well-recognised adverse effects such as reactive hyperaemia. Diazoxide is a well-established treatment for congenital hyperinsulin-aemia and insulinoma and has been used in this context for over 40 years. Trials have been small, and have looked at the medical management of insulinomas as an adjunct to surgery or in those who are inoperable. To date there has not been a large randomised controlled trial looking at the efficacy of this treatment. Recent studies have suggested a number of possible novel indications for the use of diazoxide in obesity and both T1DM and T2DM. Obesity and metabolic syndrome. Studies of cell culture and animal models have demonstrated that diazoxide induces membrane hyperpolarisation in adipocytes, an action that suppresses lipogenesis and increases lipolysis through the regulation of key insulin sensitive enzymes. Diazoxide therapy in rats produces a reduced lipogenic state and results in lower levels of plasma leptin. In an open-label non-placebo controlled study of obese human subjects, oral diazoxide when combined with a reduced calorie intake and increased physical activity resulted in additional reductions in both fasting and post-meal peak insulin levels by about 65% (p
Zitieren
APA
George, P., & McCrimmon, R. (2012). Diazoxide. Practical Diabetes, 29(1), 36-37. https://doi.org/10.1002/pdi.1655
Vancouver
George P, McCrimmon R. Diazoxide. Practical Diabetes. 2012;29(1):36-37. doi:10.1002/pdi.1655
BibTeX
@article{George2012,
author = {George, Priya and McCrimmon, Rory},
title = {Diazoxide},
journal = {Practical Diabetes},
year = {2012},
volume = {29},
number = {1},
pages = {36--37},
doi = {10.1002/pdi.1655}
}
EUVIMED